BXP.L Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 май 2024 @ 14:22):

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh...

Stats
Объем за сегодня	22 224.00
Средний объем	46 605.00
Рыночная капитализация	162.83M
EPS	£2.13 ( 2023-03-31 )
Last Dividend	£3.32 ( 2022-11-17 )
Next Dividend	£0 ( N/A )
P/E	4.56
ATR14	£0 (0.00%)

Beximco Pharmaceuticals Корреляция

10 Самые положительные корреляции
POLX.L	0.931
FRP.L	0.923
FWD.L	0.921
KCT.L	0.92
SENS.L	0.917
GRIO.L	0.917
RESI.L	0.915
WNWD.L	0.914
GSF.L	0.913
WATR.L	0.912

10 Самые отрицательные корреляции
RR.L	-0.933
REL.L	-0.932
RSVL.L	-0.928
IL0A.L	-0.922
JDW.L	-0.917
FEDF.L	-0.911
XFFE.L	-0.91
MPO.L	-0.91
JREC.L	-0.909
EMRJ.L	-0.906

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Beximco Pharmaceuticals Финансовые показатели

Annual	2022
Выручка:	£39.27B
Валовая прибыль:	£17.31B (44.09 %)
EPS:	£10.34

FY	2022
Выручка:	£39.27B
Валовая прибыль:	£17.31B (44.09 %)
EPS:	£10.34

FY	2022
Выручка:	£34.67B
Валовая прибыль:	£15.81B (45.61 %)
EPS:	£11.48

FY	2021
Выручка:	£29.49B
Валовая прибыль:	£13.92B (47.21 %)
EPS:	£11.49

Financial Reports:

No articles found.

Beximco Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£0 (N/A)	£3.32 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

Beximco Pharmaceuticals Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.32 - Stable (26.49%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£0.174	2008-06-30
Last Dividend	£3.32	2022-11-17
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	£16.75	--
Avg. Dividend % Per Year	1.38%	--
Score	3.37	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.32
Div. Directional Score	8.34	--

Next Divdend (Est)
(2024-05-24)

£0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

3.37

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2008	£0.174	1.17%
2009	£0.405	6.62%
2010	£0	0.00%
2011	£0	0.00%
2012	£0	0.00%
2013	£0	0.00%
2014	£0	0.00%
2015	£1.057	7.02%
2016	£1.730	7.40%
2017	£1.373	2.80%
2018	£1.354	2.48%
2019	£1.605	3.92%
2020	£1.766	4.37%
2021	£3.97	4.14%
2022	£3.32	2.69%
2023	£0	0.00%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TBCG.L	Dividend Knight	2023-09-07	Annually	8	3.12%
KWS.L	Dividend Knight	2023-10-05	Annually	12	0.03%
CGS.L	Dividend King	2023-07-20	Semi-Annually	33	4.73%
RDW.L	Dividend Knight	2023-09-21	Annually	31	3.30%
GRG.L	Dividend Knight	2023-09-07	Semi-Annually	32	1.71%
APTD.L	Dividend Knight	2023-08-03	Semi-Annually	32	0.82%
TSCO.L	Dividend King	2023-05-11	Semi-Annually	32	4.53%
MFX.L	Dividend Knight	2023-06-15	Annually	4	1.28%
CSN.L	Dividend Knight	2023-09-28	Semi-Annually	21	4.56%
SBRE.L	Dividend Knight	2023-08-17	Semi-Annually	7	2.15%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.124	1.500	7.53	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0759	1.200	7.47	8.96	[0 - 0.3]
returnOnEquityTTM	0.118	1.500	9.80	10.00	[0.1 - 1]
payoutRatioTTM	0.297	-1.000	7.03	-7.03	[0 - 1]
currentRatioTTM	1.797	0.800	6.02	4.81	[1 - 3]
quickRatioTTM	0.422	0.800	-2.23	-1.781	[0.8 - 2.5]
cashRatioTTM	0.0956	1.500	-0.580	-0.870	[0.2 - 2]
debtRatioTTM	0.106	-1.500	8.24	-10.00	[0 - 0.6]
interestCoverageTTM	13.34	1.000	6.17	6.17	[3 - 30]
operatingCashFlowPerShareTTM	18.77	2.00	3.74	7.49	[0 - 30]
freeCashFlowPerShareTTM	13.82	2.00	3.09	6.18	[0 - 20]
debtEquityRatioTTM	0.160	-1.500	9.36	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.437	1.000	6.06	6.06	[0.2 - 0.8]
operatingProfitMarginTTM	0.184	1.000	8.32	8.32	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.127	1.000	4.85	4.85	[0.2 - 2]
assetTurnoverTTM	0.614	0.800	9.24	7.39	[0.5 - 2]
Total Score				10.36

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	4.19	1.000	9.68	0	[1 - 100]
returnOnEquityTTM	0.118	2.50	9.87	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	13.82	2.00	5.39	6.18	[0 - 30]
dividendYielPercentageTTM	0.0634	1.500	8.42	0	[0 - 0.4]
operatingCashFlowPerShareTTM	18.77	2.00	3.74	7.49	[0 - 30]
payoutRatioTTM	0.297	1.500	7.03	-7.03	[0 - 1]
pegRatioTTM	0.344	1.500	-1.042	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.194	1.000	7.64	0	[0.1 - 0.5]
Total Score				6.32

Beximco Pharmaceuticals

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company offers allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.